CASMET December Newsletter

7/30/2019 CASMET December Newsletter

http://slidepdf.com/reader/full/casmet-december-newsletter 1/15

THE CARIBBEAN ASSOCIATION OF

MEDICAL TECHNOLOGISTS

Newsletter: Volume 1, Issue

Anguilla

St. Vincent & Grenadines

Haiti

Grenada

Dominica

The Cayman Islands

Bermuda

Belize

The Bahamas

Barbados

Jamaica

Antigua & Barbuda

Trinidad & Tobago

St. Lucia

St. Kitts & Nevis

Suriname

Guyana

The Netherland Antilles

The British Virgin Islands

For Laboratory Professionals

CONTRIBUTORS FOR DECEMBER:

Chris Seay (USA)

The Pan American Health Organization (PAHO)

Victor Farrell (Barbados)

The Bahamas Branch

Greselda Evans (Barbados)

Earther Went (Barbados)

Distributed: September 20

Word from the Liaison p

Congratulations & Looking Back p

The Development of Dengue Vaccinand their Potential use in the Amer

p

The Safe Hospitals Initiative in theWorld p

BGM 2013 p

Laboratory Mathematics Answers pg

Press Release: Christmas Downsiz pg

My New Year Resolutions pg

A NEWSLETTER FOR THE CHRISTMAS SEASON !

Season’s Greetings and Happy Holidays to all from the Education Committee! May your Xmas be all that you wish it to be, with lots of Xmas cheer and love for everyon

Have a blessed Christmas and a happy and prosperous 2013 !!!



2

2 TYPE TITLE HERE

As 2012 draws to a close, I would to express my appreciation to CASMET for doing such a great work.

As the official liaison, I have attended two Regional Council Meetings (RCM) and they both were tremendous

successes. The work to coordinate meeting places, work areas and transportation arrangement took fantastic

individual as well as team effort. I give, my personal thanks, to those individuals and teams.

As 2013 begins, please be supportive of all the activities of CASMET and AMT:

In July, AMT will hold the national meeting in Pittsburg, Pennsylvania.

In October, CASMET will have the Biennial General Meeting (BGM) in the Bahamas.

All Members of both organizations should be supportive for two reasons. First these meetings allow important

business to be accomplished, which affords Members the opportunity to have their input about the affairs of the

organization.

The second reason is to learn, as valuable educational opportunities are presented. This enables us all to stay abreast

of new information and technologies related to the healthcare field.

Therefore, let’s work to make 2013 an even greater year than 2012.

May the Christmas, New Year and holidays be a blessing to you all.

Be blessed with safe travels.

A QUOTE OF NOTE: “ You're either part of the solution or part of the

problem .” (Leroy) Eldridge Cleaver (1935-1998)

An excerpt from a speech given in San Francisco in1968



3

3

LOOKING BACK : By Victor Farrell

DID YOU KNOW THAT ??

The first meeting to introduce the formation of the Society of Medical Technologists (W.I) was held at the

Department of Pathology, University of the West Indies, Jamaica on May 29, 1953. At that time the name

agreed on was the Association of Medical Technicians.

The inauguration of the Association took place at a General Meeting held on December 9, 1953 at which

Professor Hill was elected President.

At a meeting held on September 28, 1954, it was decided that the word ‘Association’ should be replaced by

‘Society’ and that the full name should be The Society of Medical Technologists (West Indies).

Professor G. Bras succeeded Professor Hill as President in November 1956.

The decade of the mid 1960’s to mid 1970’s saw an increase in the number of Medical Technology students

from other Caribbean islands undergoing training at the Department of Pathology, U.W.I, Mona. This was

made possible largely through the financial assistance from the World Health Organization.

Up until the mid 1970’s the training of Medical Technologists was largely on the jo b, supplemented by

lectures and demonstrations.

MEMBER OF THE ORDER OF THE BRITISH EMPIRE (MBE)

Mr. Victor DaCosta Farrell of Barbados has been made a Member

of the Order of the British Empire (MBE) in the New Year Honors.

For services in the field of medical laboratory technology in Barbados

and other Caribbean counties



4

4 TYPE TITLE HERE

Immunization Newsletter: Pan American Health Organization, October 2011

The Development of Dengue Vaccines and Their Potential Use in the Americas: Volume XXXII

is a disease caused by an infection of four serologically and genetically related but distinct flaviviruses,

denominated dengue viruses 1 to 4. Aedes mosquitoes,

principally of the species Aedes aegypti, that bite infected

persons infect themselves and then serve as the vector of the

infection between people. In humans, 50 – 90% of primary

infections remain asymptomatic.

When it clinically manifests, dengue has a spectrum of

clinical presentations ranging from a debilitating fever to

potentially lethal severe complications (severe plasmaleakage, severe bleeding, or severe organ involvement). A key

risk factor for severe dengue is a previous infection with a

dengue virus of a different serotype.

Starting in the 1960s, dengue has gradually become a leading

cause of hospitalization and death among children and adults

in many countries of South-east Asia, the Western Pacific,

and Latin America and the Caribbean. Because Aedes aegypti

is the main vector, dengue flourishes in tropical and

subtropical countries mainly among residents of urban andperi-urban poor areas but does not spare more affluent

neighbourhoods.

Dengue burden globally and in the Americas

One third (2.5 billion people) of the world population live at

risk of a dengue infection. Worldwide, dengue is now

reported in over 110 countries; it is estimated that up to 50

million infections, 500,000 cases of severe dengue and 20,000

deaths occur each year.

In Latin America and the Caribbean, dengue virus

transmission now occurs in all countries and territories except

for Uruguay and continental Chile. In 2010, 1,663,276 dengue

cases were reported throughout the Americas — the highest

number ever recorded (Graph). This number of cases

corresponds to an annual rate of 3.2 cases per 1,000 people.

Of the total dengue cases, 48,954 cases were classified as

severe dengue and 1,194 case-patients deaths.

Although the incidence remains historically high, denincidence appears lower in 2011.

As of November 18, 2011 (epidemiological week

997,974 cases had been reported, of which 17,055 were sev

dengue and 708 case-patients deaths.

At country level, severe dengue manifests itself in ei

children or adolescent and adults. The distinct age gr

pattern depends on the previous waves of dengue epidem

and on the dengue virus serotype types that circula

previously. El Salvador and Venezuela are examplescountries where dengue occurs in children; in contr

Mexico, Colombia, and Paraguay are examples of count

where all age groups, in particular adolescents and yo

adults, are affected. Incidence does not vary between gende

The integrated management strategy for dengue

prevention and control

Countries have made important efforts to contain and c

dengue burden. Since 2003, PAHO has supported Mem

States with the implementation of an integrated strategy

dengue prevention and control. Its core element i

management model designed to strengthen national progr

interprogrammatically through stronger partnerships am

public entities at all levels, communities, and the pri

sector. Activities are organized into five components: pat

care; social communication; epidemiological surveilla

vector control; and laboratory capacity. Until October 2

the strategy had been adopted by 21 countries

systematically evaluated in 16.

In recent years, recognizing the key role of communit

involvement in dengue prevention and control, PA

reinforced the communication component of the integr

strategy with a methodology called COMBI (Communica

for Behavioral Impact).



5

5

IMMUNIZE AND PROTECT YOUR FAMILYIMMUNIZE AND PROTECT YOUR FAMILY

Through the integration of health information-education

communication, social mobilization and marketing, and

training and situation analysis research, this methodology

aims to motivate and encourage communities to adopt and

maintain key preventive actions for dengue.

Clearly, dengue prevention and control has a history in the

Americas stretching back several decades. At least since

2003, dengue prevention and control is anchored on a well-

defined strategy based in the integrated management of

different components. In a few years, vaccination and

transgenic Aedes aegypti mosquitoes incompetent for dengue

transmission (being developed and tested in Asia and the

Americas) might become an additional component and tool of

this strategy, and thus complement and strengthen ongoing

actions.

Dengue vaccine development

Dengue vaccine development has faced unique challenges due

to the peculiar nature of dengue virus infection. Although

significant

advances have been made since the mid- 1960s, the pathogenesis of severe dengue is still not completely

explained, in part because of the absence of an animal model

for the clinical disease. In simplified terms, the leading

hypothesis has postulated that the

transient protection conferred by one dengue virus serotype

against infection by the three heterologous serotypes actually

creates the conditions for an enhanced immune response and

thus for severe dengue, should a subsequent secondary

infection by a heterologous serotype occur. This phenomenon,

commonly denominated antibody-dependent enhancement

(ADE), implies that any dengue vaccine must provide a

simultaneous and long-term protection against all four dengue

virus serotypes, i.e. it needs to be tetravalent. Although

neutralizing antibodies are thought to be the immunological

correlated for protection, the required antibody quantity is still

uncharacterized — a lack in knowledge that has also

contributed to the delays in vaccine development.

In spite of these challenges, the dengue vaccine pipelin

considerable and includes candidate vaccines at both the

clinical and clinical development stage. The Table (pg

summarizes five candidate vaccines in active clin

development. Three of these vaccines are live-attenuated

tetravalent, but vary in the employed virus and the ac

dengue virus antigen; the two additional candidate vacc

are non-replicating.

The candidate vaccine that is more advanced in its clin

development is a live-attenuated tetravalent vaccine ca

ChimeriVax-DEN. This vaccine was obtained by replacin

the yellow fever vaccine 17D strain the genes coding for

membrane and envelope proteins for the corresponding g

of each of the four dengue viruses. The vaccine was dee

safe and efficacious in phase I – II clinical trials. Consequen

phase III clinical trials started in October 2010 in Austr

(age groups included: 18 – 60 years) and in June 201

South-east Asia (2 – 14 years). A phase III trial is also plan

at sites in five Latin American countries, namely Br

Colombia, Honduras, Mexico and Puerto Rico.

Over 20,000 children and adolescents aged 9 – 16 years being enrolled in this trial, expected to last until August 2

In all these phase III trials, the vaccine is administr

subcutaneously in a 3-dose schedule at 0, 6 and 12 months

First efficacy and safety results from these phase III trials

be available in 2013; if results were satisfactory, the vac

developer plans to seek licensure as early as 2014 – 2

During the first five years following licensure, the ann

production is projected at 100 million doses. W

substantial, at least initially vaccine availability would cle

be much smaller than the potential worldwide demand.

information has been released on the possible price of

vaccine.

In addition to clinical stage candidate vaccines, a large var

of candidates are in preclinical development. Some of th

candidate vaccines potentially show superior product pro

and might thus become a second generation of den

vaccines.



6

6 TYPE TITLE HERE

References and further readings:

1. Beatty ME, Beutels P, Meltzer MI, et al. Health economics of dengue: A systematic literature review and expert panel’s assessment. American Journof Tropical Medicine and Hygiene 2011, 84:473 –88. PMID:21363989

2. Coller BA and Clements DE. Dengue vaccines: Progress and challenges. Current Opinion in Immunology 2011, 23:391 –8. PMID:21514129

3. Guzman MG, Halstead SB, Artsob H, et al. Dengue: A continuing global threat. Nature Reviews Microbiology 2010, 8:S7 –16. PMID:21079655

4. San Martín JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the Americas over the last three decades: A worrisome reality. American Journal of Tropical Medicine and Hygiene 2010, 82:128 –35. PMID:20065008

5. San Martín JL and Brathwaite-Dick O. Integrated strategy for dengue prevention and control in the Region of the Americas. Revista Panamericana deSalud Publica 2007, 21:55 –63. PMID:17439693

6. Sanofi-Aventis. Study of a novel tetravalent dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America (ClinicalTrials.govidentifier: NCT01374516). Available online at: http://clinicaltrials.gov/ct2/show/NCT01374516 (accessed on 11/22/2011).

7. Schmitz J, Roehrig J, Barrett A, and Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 201129:7276 –84. PMID:21781998

8. Shepard DS, Coudeville L, Halasa YA, et al. Economic impact of dengue illness in the Americas. American Journal of Tropical Medicine and Hygiene2011, 84:200 –7. PMID:21292885

9. Suaya JA, Shepard DS, Siqueira JB, et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. American Journal oTropical Medicine and Hygiene 2009, 80:846 –55. PMID:19407136

10. Whitehorn J and Simmons CP. The pathogenesis of dengue. Vaccine 2011, 29:7221 –8. PMID:21781999

TABLE: Dengue candidate vaccines in active clinical development, October 2011*

Clinical trial phase Developer Approach (details) DEN DEN V antigens Valencies

Phase 3Sanofi Pasteur Live attenuated

YF17D/DENV chimeras)prM/E Tetravalent

Phase 1 Inviragen Live attenuated (DENV2-PDK53 DENV chimeras)

Whole virus Tetravalent

Phase 1 US National Instituteof Health; licensees:Biological E, Butantan,Panacea, Vabiotech

Live attenuated(targeted mutagenesisDENV chimeras)

Whole virus Tetravalent

Phase 1 Merck Recombinant subunit 80% of E Monovalent

Phase 1 NMRC/WRAIR DNA prM/E Monovalent

Adapted from Julia Schmitz and Joachim Hombach World Health Organization / Initiative for Vaccine Research (WHO/IVR).

Overall, the considerable dengue vaccine pipeline promises

that several and diverse dengue vaccines might become

available within a decade or so after a first vaccine is licensed.

Conclusions

As in other continents, dengue burden has notably increased in

Latin America and the Caribbean over the past decades.

Although an integrated management strategy for dengue

prevention and control was implemented in several countries

throughout the Region, anticipation exists for vaccination to

complement current actions.

For the first time in the history of the Americas’ expanded

immunization programs (EPI), discussion on the potential use

of a vaccine has started even before the vaccine has been

licensed.

In the next few years, clinical trials are being continued

partially concluded, thus generating needed additional sa

and efficacy data. Given the peculiar nature of den

experts are actively discussing long-term evaluations of

interaction of mass vaccination and natural infec

occurrence. Whilst some level of uncertainty persist

window of opportunity is nonetheless present for nati

dengue and immunization programs to — similarly to w

has been done for other new vaccines — collaborate tow

supporting national level decision-making on a pos

dengue vaccine introduction through the use of econo

evaluations grounded in local data and towards ensu

surveillance systems able to inform vaccination policies

monitor vaccination effectiveness and impact. ■



7

7

Prevention is better than treatment” is more than a wise proverb. It is

also at the center of the efforts of every health system that values the

protection of the life and well-being of its population. It is also the

challenge faced by disaster management systems, which aim at

reducing risk to acceptable levels and thus contributing to sustainable

development.

The Safe Hospitals Initiative, started in the Americas in 2004, has

influenced the thinking of the 168 United Nations Member States,

leading to the commitment as a goal for 2015 that all new hospitals

should be built in such a way that continued operation in disasters is

ensured and that existing hospitals should progressively improve their

safety levels in this respect.

The development of instruments for safety evaluations, in order to

understand and analyze the situation of hospitals, compare results, and

prioritize interventions, proved to be the best strategy to move from

theory to practice, giving priority to interventions in those critical

services for which continuous operation can represent the difference

between life and death.

Presently, the Hospital Safety Index (HSI) is the most widely used

instrument of this kind in the world. In March 2012, 31 countries and

territories in the Americas reported its use in setting priorities. It is

also one of the central elements in the implementation of national and

subnational policies and programs for safe hospitals. More than 1,400

hospitals have been evaluated with the HSI. The results showed that

51% are in category A, that is, they have high probability of

continuing to function in disasters; 37% in category B, meaning that

they can resist a disaster but that equipment and critical services are at

risk; and 12% in category C, which indicates that they will very

probably stop functioning in disasters and be unable to guarantee the

lives of their patients and personnel.

.

The Safe Hospitals Initiative in the World

Posted in Issue 117 - April 2012 Perspective

http://new.paho.org/disasters/newsletter/index.php?option=com_content&view=category&id=232%3Aissue-117-april-2012-perspective&layout=blog&Itemid=303&lang=en





8

8 TYPE TITLE HERE

WHO representatives from around the world met in Turkey to study the hospital safety evaluation instruments used in th

different continents and agreed to take the HSI as a basis for a global instrument that can be adapted to different realities.

Some regions of the world adopted the HSI as such, while others adapted it to their own context.

Countries in Europe that implemented actions for safe hospitals translated the HSI into their respective languages and hav

applied it without variations. In the countries of the Eastern Mediterranean, where there are high levels of social and politica

violence that require temporary and variable health services to be set up, the structural component is much less important tha

the availability and capacity of the health workers who operate these services.

In the countries of South East Asia, with highly diverse realities, the main focus is in having a series of tools based on th

HSI, making it possible for the countries to apply the instruments and adapt the components to their levels of developme

and implementation of the Safe Hospitals Initiative. The countries of the Western Pacific, in turn, developed a series of goa

(benchmarks) aimed at steadily increasing the response capacity of hospitals in the region. Although they did not try to assignumerical values in ranking hospital safety levels, they have established mechanisms for prioritization based on hospit

complexity. In Africa, the application of the HSI has begun in Uganda, and the region is currently generating common polic

papers to delimit the framework of action for disaster risk management in the health sector and the implementation of th

program of safe hospitals, with the participation of experts from PAHO.

The evaluation of the safety of medium and small hospitals and health facilities of lower complexity is another important ste

that many countries of the Americas have initiated. The results to date show that it is necessary to check the instruments an

the criteria for relative assessment in greater detail, so that they can provide useful results, especially for those communitie

that only have lower-complexity health facilities and, accordingly, should ensure their operation with no interruptions. ■

The Safe Hospitals Initiative in the World cont’d:

A Politically Correct Holiday Greeting--------------------------------------

Best wishes for an environmentally conscious, socially responsible, low

stress, non-addictive, gender-neutral, winter solstice holiday, practiced within

the most joyous traditions of the religious persuasion of your choice, but with

respect for the religious persuasion of others who choose to practice their

own religion as well as those who choose not to practice a religion at all;

plus...A fiscally successful, personally fulfilling, and medically uncomplicated

recognition of the generally accepted calendar year 2013, but not without due

respect for the calendars of choice of other cultures whose contributions have

helped make our society great, without regard to the race, creed color,

religious, or sexual preferences of the wishes.

Disclaimer: This greeting is subject to clarification or withdrawal. It implies no

promise by the wisher to actually implement any of the wishes for her/himself or

others and no responsibility for any unintended emotional stress these greetings may

bring to those not caught up in the holiday spirit .

http://www.edlin.org/humour/xmas_jokes.html





9

9

The city of Nassau has a variety of historic buildings as well as many sightseeing opportunities.

Engage the service of our many knowledgeable tour guides to keep you busy.

NASSAU CITY TOUR

Learn about the history and culture of The Bahamas on this one o

kind Nassau sightseeing tour. You’ll have the opportunity to visit

old romantic sector of Nassau, ancient Forts, historic sites,

churches, and commercial sectors.

HORSE AND CARRIAGE

Absolutely the most authentic way to tour the center of Nassau is

by riding in a horse drawn carriage. Its fun, informative and you

get the benefit of a breeze to beat the heat.

BOTANICAL GARDENS

Garden enthusiasts will love this display of more

than 600 flowering trees and shrubs. Visit these 18

acres of tropical beauty.

ARDASTRA GARDENS AND ZOO

This exotic tropical garden houses more than 300

birds, mammals, and reptiles from the Bahamas

and around the world. Come enjoy the world

famous flamingo marching band.

NATIONAL ART GALLERY

Bahamian artists exhibit numerous works here,ceramics, paintings, sculptures and photography.

PIRATES OF NASSAUAn interactive pirate attraction in the heart of Down

Town Nassau, come face to face with pirates like

Black Beard and his rogue of fellow pirates.

BEACHES

If you like the idea of soaking up some sun and lazing

around the beach at your leisure you will definitely find

our beaches irresistible.



10

10 TYPE TITLE HERE

ARAWAK CAY FISH FRY

Here you can mingle with the locals and enjoy native

food and beverages. You must try the conch salad

and conch fritters.

DOLPHIN ENCOUNTERS

On a luxuriant coconut palm paradise, relax and

have fun as you meet our beloved marine

mammals face to face. Be entertained by world

famous dolphin and sea lions.

SNORKELING

Swim with schools of tropical colourful fish in

shallow waters off Nassaus famous reefs.

HARBOUR ISLAND DAY AWAY

Visit the famous pink beach of Harbour Island tour

the island in a golf cart or take a horse back ride

on the beach.

SCUBA DIVING

If you ever wanted to try scuba diving Nassau isthe perfect place for it.

ROSE ISLAND DAY AWAY

Enjoy a scenic boat ride on a triple deck catamarantravel Nassau picturesque water to Rose Island

where you can take part in various beach and

water activities, relax on a sun drenched beach or

strech out in a hammock under a palm tree.

SUBMAMINE ADVENTURE

Take an underwater cruise in your own personal

submarine.



1

11



12

12 TYPE TITLE HERE

Answers to Laboratory Mathematics Questions

Please note that there was an error to question # 2

It should have read: You need 200ml of a 1:300 solution of Glucose /L. You have a 1:100 solution. How would you prepare the desired quantity of 1:300 solution? ANS: 66.66 ml of stock iodine made up to 200 m

with diluent.

1. A stock potassium solution has a concentration of 500 mg%. A 1/5 dilution of this standard is

made. What would be the concentration of the final solution? ANS: 100mg%

2. You need 200ml of a 1:300 solution of Glucose /L. What dilution is necessary to prepare a

working standard containing 5mg / 100 ml.

3. Give the ratio of 3ml of serum diluted with 17ml of water. Give the dilution of the solution.

ANS: 1/ 6.666 OR 1/6.67

4. A glucose standard contains 5 mg of glucose/ml. A 1/10 dilution of this standard would contain

how much glucose? ANS: 0.5 mg/ml

5. You have a stock standard with a stated concentration of 1000 mg/dl. How would you prepare

50 ml of a 5.0 mg/dl working standard? ANS: 0.25 ml of stock made up to 50ml with

diluent.

6. You need 50 ml of HCL solution which is 0.02N. You have on hand 0.5N solution. How would

you prepare this solution to give the desired volume and concentration? ANS: 2.0 ml of 0.5N

HCL made up to 50 ml with diluent.

7. If 1 ml of a 1:4 dilution is further diluted by adding to it 1.5 ml of distilled water, the final

dilution is: ANS: 1/10

a. 1:5

b. 1:6

c. 1:10

d. 1:25

8. A stock standard solution contains 200 g of glucose /l. What dilution is necessary to prepare a

working standard containing 5mg /100 ml. ANS: 1/400

a. 1/500 d. 1/100

b. 1/1000 e. 1/400

c. 1/4000

9. The following quantities are placed in a test tube: 0.1 sample, 2.9ml of diluent, 0.5 ml of

reagent #1, 0.5 ml of reagent #2. What is the final dilution of the sample? ANS: 1/40



13

13

Today's global challenges require the North Pole to continue to look for better, more competitive steps. Effective

immediately, the following economy measures are to take place in the "Twelve Days of Christmas" subsidiary:1. The partridge will be retained, but the pear tree never turned out to be the cash crop forecasted. It will be

replaced by a plastic hanging plant, providing considerable savings in maintenance.

2. The two turtle doves represent a redundancy that is simply not cost effective. In addition, their romance

during working hours could not be condoned. The positions are therefore eliminated.

3. The three French hens will remain intact. After all, everyone loves the French.

4. The four calling birds were replaced by an automated voice mail system, with a call waiting option. An

analysis is underway to determine who the birds have been calling, how often and how long they talked.

5. The five golden rings have been put on hold by the Board of Directors. Maintaining a portfolio based on one

commodity could have negative implications for institutional investors. Diversification into other precious

metals as well as a mix of T-Bills and high technology stocks appear to be in order.6. The six geese-a-laying constitutes a luxury which can no longer be afforded. It has long been felt that the

production rate of one egg per goose per day is an example of the decline in productivity. Three geese will

be let go, and an upgrading in the selection procedure by personnel will assure management that from now

on every goose it gets will be a good one.

7. The seven swans-a-swimming is obviously a number chosen in better times. Their function is primarily

decorative. Mechanical swans are on order. The current swans will be retrained to learn some new strokes

and therefore enhance their outplacement.

8. As you know, the eight maids-a-milking concept has been under heavy scrutiny by the EEOC. A male/female

balance in the workforce is being sought. The more militant maids consider this a dead-end job with no

upward mobility. Automation of the process may permit the maids to try a-mending, a-mentoring or a-

mulching.

9. Nine ladies dancing has always been an odd number. This function will be phased out as these individuals

grow older and can no longer do the steps.

10. Ten Lords-a-leaping is overkill. The high cost of Lords plus the expense of international air travel prompted

the Compensation Committee to suggest replacing this group with ten out-of-work congressmen. While

leaping ability may be somewhat sacrificed, the savings are significant because we expect an oversupply of

unemployed congressmen this year.

11. Eleven pipers piping and twelve drummers drumming is a simple case of the band getting too big. A

substitution with a string quartet, a cut back on new music and no uniforms will produce savings which will

drop right down to the bottom line.

12. We can expect a substantial reduction in assorted people, fowl, animals and other expenses. Thoughincomplete, studies indicate that stretching deliveries over twelve days is inefficient. If we can drop ship in

one day, service levels will be improved.

Regarding the lawsuit filed by the attorneys association seeking expansion to include the legal profession ("thirteen

lawyers-a-suing"), action is pending.

Lastly, it is not beyond consideration that deeper cuts may be necessary in the future to stay competitive. Should

that happen, the Board will request management to scrutinize the Snow White Division to see if seven dwarfs is the

right number.

Adapted from: http://www.dancentury.com/xmas.html#.UOBwSXen3IV

http://www.dancentury.com/xmas.html#.UOBwSXen3IV

http://www.dancentury.com/xmas.html#.UOBwSXen3IV



14

14 TYPE TITLE HERE

Adapted from: http://www.123newyear.com/newyear-poems/my-new-years-resolution-by.html

I will not throw the cat out the window

Or put a frog in my sister's bed

I will not tie my brother's shoelaces together

Nor jump from the roof of Dad's shed

I shall remember my aunt's next birthday

And tidy my room once a week

I'll not moan at Mum's cooking (Ugh! fish fingers again!)

Nor give her any more of my cheek.

I will not pick my nose if I can help it

I shall fold up my clothes, comb my hair,

I will say please and thank you (even when I don't mean it)

And never spit or shout or even swear.

I shall write each day in my diary

Try my hardest to be helpful at school

I shall help old ladies cross roads (even if they don't want to)

And when others are rude I'll stay cool.I'll go to bed with the owls and be up with the larks

And close every door behind me

I shall squeeze from the bottom of every toothpaste tube

And stay where trouble can't find me.

I shall start again, turn over a new leaf,

leave my bad old ways forever

shall I start them this year, or next year

shall I sometime, or .....?

By Robert Fisher

http://www.123newyear.com/newyear-poems/my-new-years-resolution-by.html

http://www.123newyear.com/newyear-poems/my-new-years-resolution-by.html



15

Education Committee Contact Information:

Earther Went (Chairperson): [email protected]

Sashoy Duncan: [email protected]

Marcia Robinson- Walters: [email protected]

Delphia Theophane: [email protected]

Tamara Chambers: [email protected]

Janice Wissart: [email protected]

This Newsletter is a production of the

Education Committee of the Caribbean

Association of Medical Technologists

All rights reserved @ March 31St 2012

mailto:[email protected]








Documents

CASMET December Newsletter